Posted by Michael Wonder on 05 Dec 2024
Exelixis provides regulatory update related to supplemental new drug application for cabozantinib (Cabometyx) for the treatment of patients with previously treated advanced neuroendocrine tumors
26 November 2024 - 26, 2024-- Exelixis today announced that the US FDA has notified the company that the supplemental new drug application for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors will be discussed at an Oncologic Drugs Advisory Committee meeting in March 2025.
The supplemental new drug application is based on the final results of the Phase 3 CABINET pivotal trial, conducted by the National Cancer Institute's National Clinical Trials Network, evaluating cabozantinib compared with placebo in advanced pancreatic neuroendocrine tumours and advanced neuroendocrine tumours.
